# Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD

> **NCT02123199** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol (Onbrez®) /QAB149

## Key facts

- **NCT ID:** NCT02123199
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02123199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02123199, "Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02123199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*